Head-to-head evidence
IcoSema vs LY2963016
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline
IcoSema · Kyinsu
Marketed by Novo Nordisk
NCT05352815 · Phase 3 · completed
Participants were randomized 1:1 to IcoSema or active insulin icodec, but the study was open-label rather than blinded. The primary HbA1c endpoint was statistically significantly better with IcoSema, although HbA1c is a surrogate metabolic measure rather than a hard clinical endpoint.
LY2963016 · Basaglar
Marketed by Eli Lilly
NCT01421459 · Phase 3 · completed
The study was randomized, triple-blind, and active-controlled, with 759 participants, but its primary endpoint was HbA1c, a laboratory surrogate rather than a hard clinical outcome. The prespecified non-inferiority comparison was met: the 95% confidence interval for the treatment difference remained below the +0.4% margin.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: IcoSema's landscape · LY2963016's landscape